Perrigo, in an effort to hive off $175 million a year in costs, is laying off 6% of its workforce, among other steps.
As Lundbeck cuts staff and reshuffles R&D, one of its drug candidates has come out a winner.
The job cuts at Merck have been massive ever since its 2009 merger with Schering-Plough, 36,000 in 5 years. They have almost run their course, but manufacturing will make up most of what is left as it continues to shed manufacturing plants.
Healthcare was one of the strongest segments at German conglomerate Siemens last quarter, both in terms of sales growth and profitability. That could help insulate this business, comprised mostly of imaging and diagnostics, from an ongoing restructuring that aims to trim employees and costs from its worst performing businesses.
Now that it's teamed up with Novartis' consumer health unit to form an industry-leading joint venture, GlaxoSmithKline's OTC business is bigger than ever. But its payroll is about to get smaller, with 350 layoffs hitting the operation.
Zimmer will close its Carlsbad, CA, dental headquarters following its looming $13 billion merger with Biomet, resulting in an unspecified number of layoffs. The plant closure will occur in 12 months, say internal company emails sent to both companies' employees that were obtained by FierceMedicalDevices.
The big asset swap between GlaxoSmithKline and Novartis may have given each just what it wanted, but the deal continues to play out poorly for workers, with GSK planning to close its Pittsburgh office where it has about 275 employees working for its consumer health unit.
Japan's Eisai has decided to follow the cost-cutting trend of many of its multinational counterparts and lay off a quarter of its U.S. commercial and regional corporate services units, which currently employ about 850 people. The unit said the 200-plus staff reductions would not affect manufacturing or R&D units.
Japan's Eisai is taking out the budget ax and chopping more than 200 jobs out of its U.S. operations. A spokesperson for the company tells FierceBiotech tonight that the cuts will center on Eisai's commercial and regional corporate services units, which employ about 850 people. She adds: "The restructuring will not affect our manufacturing or R&D units."
Just a couple of weeks after fellow Japanese drugmaker Daiichi Sankyo announced a layoffs drive as part of a U.S. revamp, Eisai is doing the same. Two of its units in the country are headed for a 25% shrinkage, the company said Thursday.